Relief Therapeutics Holding SA (RLFTF)
OTCMKTS
· Delayed Price · Currency is USD
2.700
-0.340 (-11.18%)
Apr 28, 2025, 3:47 PM EDT
RLFTF Income Statement
Financials in millions CHF. Fiscal year is January - December.
Millions CHF. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Operating Revenue | 8.42 | 6.03 | 6.08 | 3.32 | - | Upgrade
|
| Revenue | 8.42 | 6.03 | 6.08 | 3.32 | - | Upgrade
|
| Revenue Growth (YoY) | 39.52% | -0.79% | 83.11% | - | - | Upgrade
|
| Cost of Revenue | 2.58 | 1.92 | 1.25 | 0.75 | - | Upgrade
|
| Gross Profit | 5.84 | 4.11 | 4.83 | 2.57 | - | Upgrade
|
| Selling, General & Admin | 9.83 | 19.43 | 24.05 | 15.14 | 5.47 | Upgrade
|
| Research & Development | 1.36 | 1.33 | 12.39 | 19.02 | 13.67 | Upgrade
|
| Other Operating Expenses | -0.29 | -0.11 | -0.51 | 0.61 | 0.23 | Upgrade
|
| Operating Expenses | 13.46 | 23.97 | 39.79 | 36.81 | 19.36 | Upgrade
|
| Operating Income | -7.62 | -19.85 | -34.96 | -34.24 | -19.36 | Upgrade
|
| Interest Expense | -0.04 | -0.03 | -0.13 | -0.19 | -0.1 | Upgrade
|
| Interest & Investment Income | 0.19 | 0.09 | 0.02 | 0.04 | 0.01 | Upgrade
|
| Currency Exchange Gain (Loss) | -0.09 | -0.07 | -0.37 | 0.06 | -0.4 | Upgrade
|
| Other Non Operating Income (Expenses) | -0.06 | -0.84 | -1.79 | -1.1 | -0.05 | Upgrade
|
| EBT Excluding Unusual Items | -7.62 | -20.7 | -37.24 | -35.43 | -19.9 | Upgrade
|
| Merger & Restructuring Charges | - | - | - | -1.1 | - | Upgrade
|
| Impairment of Goodwill | - | -6.02 | -1.64 | - | - | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | 0.45 | -0.05 | -1.2 | Upgrade
|
| Gain (Loss) on Sale of Assets | 0.9 | 0.13 | - | - | 3.38 | Upgrade
|
| Asset Writedown | -16.83 | -89.88 | -24.78 | - | 11.2 | Upgrade
|
| Other Unusual Items | 4.19 | 4.78 | 8.89 | 1.06 | 0.25 | Upgrade
|
| Pretax Income | -19.36 | -111.68 | -54.32 | -35.53 | -6.26 | Upgrade
|
| Income Tax Expense | -2.24 | -13.5 | -3.53 | -0.82 | 1.57 | Upgrade
|
| Net Income | -17.12 | -98.18 | -50.79 | -34.71 | -7.83 | Upgrade
|
| Net Income to Common | -17.12 | -98.18 | -50.79 | -34.71 | -7.83 | Upgrade
|
| Shares Outstanding (Basic) | 13 | 12 | 11 | 9 | 6 | Upgrade
|
| Shares Outstanding (Diluted) | 13 | 12 | 11 | 9 | 6 | Upgrade
|
| Shares Change (YoY) | 6.71% | 11.18% | 17.67% | 48.89% | 14.70% | Upgrade
|
| EPS (Basic) | -1.37 | -8.35 | -4.80 | -3.86 | -1.30 | Upgrade
|
| EPS (Diluted) | -1.37 | -8.35 | -4.80 | -3.86 | -1.30 | Upgrade
|
| Free Cash Flow | -2.93 | -18.06 | -24.16 | -35.72 | -18.25 | Upgrade
|
| Free Cash Flow Per Share | -0.23 | -1.54 | -2.29 | -3.98 | -3.03 | Upgrade
|
| Gross Margin | 69.41% | 68.17% | 79.44% | 77.42% | - | Upgrade
|
| Operating Margin | -90.52% | -329.07% | -574.92% | -1030.89% | - | Upgrade
|
| Profit Margin | -203.39% | -1627.40% | -835.22% | -1045.02% | - | Upgrade
|
| Free Cash Flow Margin | -34.81% | -299.32% | -397.29% | -1075.52% | - | Upgrade
|
| EBITDA | -5.58 | -17.07 | -31.49 | -32.38 | -19.36 | Upgrade
|
| EBITDA Margin | -66.27% | -282.98% | - | - | - | Upgrade
|
| D&A For EBITDA | 2.04 | 2.78 | 3.47 | 1.86 | 0 | Upgrade
|
| EBIT | -7.62 | -19.85 | -34.96 | -34.24 | -19.36 | Upgrade
|
| EBIT Margin | -90.52% | - | - | - | - | Upgrade
|
| Revenue as Reported | 9.83 | 6.33 | 7.11 | 4.49 | 0.27 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.